Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity

Executive Summary

Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.

You may also be interested in...



Bristol’s Focus Returns To IO Following Celgene Vote

Q1 Earnings Preview: With the positive vote on its merger with Celgene behind it, Bristol now needs to focus on growing its immuno-oncology business, where several upcoming catalysts could bolster Opdivo.

Celgene/Bristol: Happy Union Or Runaway Bride?

Wellington, the largest institutional shareholder in Bristol, and activist firm Starboard both have publicly opposed the Bristol/Celgene merger but the strong crossover of investors in both biopharmas suggests the deal will still obtain approval.

Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off

Withdrawal of filing of CheckMate 227 data in patients with high tumor mutational burden (TMB) means another delay for Opdivo in first-line lung cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel